LYPD1 and neoplasm: Furthermore, we demonstrate the preclinical efficacy and non-human primate toxicology profile of QZC131, an anti-LYPD1 TCB with bivalent low-affinity anti-LYPD1 antigen-binding fragments (Fabs) and monovalent anti-CD3 scFv that selectively targets LYPD1high-medium-expressing tumor cells with high potency while sparing LYPD1low-expressing tumor cells.